The ED95 Dose of Sugammadex to Reverse Rocuronium-Induced Deep Neuromuscular Block Back to Shallow Neuromuscular Block

Launched by ANKARA UNIVERSITY · May 2, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating how effective a specific dose of sugammadex is in reversing a deep state of muscle relaxation (known as deep neuromuscular block) caused by a medication called rocuronium, bringing it back to a lighter state (known as shallow neuromuscular block). The goal is to find out the right amount of sugammadex that can help 95% of patients achieve this lighter state within 5 minutes after getting the medication. This is important because it can help ensure that patients recover more quickly from anesthesia during elective surgeries.

To participate in this trial, individuals should be between the ages of 18 and 75, have a body mass index (BMI) between 18.5 and 24.9, and be classified as ASA physical status 1 or 2, which means they are generally healthy or have mild health issues. However, people with certain conditions, like allergies to the study drugs, kidney or liver problems, or those undergoing emergency surgeries, will not be eligible. Participants can expect to receive the study drug and be monitored closely to see how well it works in reversing the effects of anesthesia. This trial is currently not recruiting participants, but it aims to gather important information to improve care in surgical settings.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • BMI: 18.5-24.9 kg/m2
• • ASA 1 and 2
• • Patients undergoing elective surgery
• Exclusion Criteria:
• • Allergic reactions to study drugs
• • Planned rapid sequence anesthesia induction
• • Patient refusal
• • Emergence surgery
• • Neuromuscular diseases
• • Renal disease or failure with elevated creatinine above 2.0 mg/dL
• • Liver failure